Schedule of revenues disaggregated by business operations and timing of revenue recognition |
| | | | | | | | | Three Month Period Ended: | | | March 31, | | March 31, | | | 2023 | | 2022 | Research and development services (over-time) | | $ | 87,907 | | $ | 219,898 | Clinical laboratory testing services (point-in-time) | | | 3,003,022 | | | 4,331,867 | Clinical laboratory testing services (over-time) | | | 938,080 | | | 1,158,375 | Product and authentication services (point-in-time): | | | | | | | Supply chain | | | 27,636 | | | 115,463 | Large Scale DNA Production | | | 253,626 | | | — | Asset marking | | | 97,343 | | | 141,657 | MDx test kits and supplies | | | — | | | 180,023 | Total | | $ | 4,407,614 | | $ | 6,147,283 |
| | | | | | | | | Six Month Period Ended: | | | March 31, | | March 31, | | | 2023 | | 2022 | Research and development services (over-time) | | $ | 213,964 | | $ | 325,591 | Clinical laboratory testing services (point-in-time) | | | 6,077,436 | | | 6,205,589 | Clinical laboratory testing services (over-time) | | | 2,377,961 | | | 2,484,775 | Product and authentication services (point-in-time): | | | | | | | Supply chain | | | 439,973 | | | 527,295 | Large Scale DNA Production | | | 381,131 | | | — | Asset marking | | | 179,901 | | | 246,895 | MDx test kits and supplies | | | — | | | 522,844 | Total | | $ | 9,670,366 | | $ | 10,312,989 |
|
Schedule of reconciliation of cash, cash equivalents and restricted cash to amounts shown in statement of cash flows |
| | | | | | | | | March 31, | | September 30, | | | 2023 | | 2022 | Cash and cash equivalents | | $ | 12,287,228 | | $ | 15,215,285 | Restricted cash | | | 750,000 | | | — | Total cash, cash equivalents and restricted cash | | $ | 13,037,228 | | $ | 15,215,285 |
|
Schedule of anti-dilutive securities not included computation of net loss per share |
| | | | | | | 2023 | | 2022 | Warrants | | 7,295,588 | | 2,239,963 | Restricted Stock Units | | 282,640 | | — | Stock options | | 2,206,336 | | 1,067,614 | Total | | 9,784,564 | | 3,307,577 |
|